ESMO 2022 | Recent advances in targeted therapies for TNBC

Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium discusses recent advances in targeted therapy for triple-negative breast cancer (TNBC), including the development of clinical trials combining antibody-drug conjugates (ADCs) with immunotherapy, as well as for patients with HER2-low breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.